+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Lipid-lowering effects of oleanolic acid in hyperlipidemic patients

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Oleanolic acid (OA) is a pentacyclic triterpenoid compound extracted from olea europaeal, a traditional Chinese medicine herb. OA has been used in the clinic as a hepatoprotective medicine in China since 1970s. In our previous study, we observed that OA could ameliorate hyperlipidemia in animal models. In the present study, we conducted a small-scale clinical trial to evaluate the hypolipidemia effect of OA in hyperlipidemic patients. Hyperlipidemic patients were administrated with OA for four weeks (4 tablets once, three times a day). The blood samples of the patients were collected before and after OA treatment. The biological parameters were measured. Furthermore, three patients’ blood samples were studied with DNA microarray. After OA administration, the TC, TG, and HDLC levels in serum decreased significantly. DNA microarray analysis results showed that the expressions of 21 mRNAs were significantly changed after OA treatment. Bioinformatics analysis showed 17 mRNAs were up-regulated and 4 mRNAs were down-regulated significantly after OA treatment. Five mRNAs (CACNA1B, FCN, STEAP3, AMPH, and NR6A1) were selected to validate the expression levels by qRT-PCR. Therefore, OA administration differentially regulated the expression of genes involved in lipid metabolism. The data showed a clinical evidence that OA could improve hyperlipidemia and also unveiled a new insight into the molecular mechanisms underlying the pharmacological effect of OA on hyperlipidemia.

          Related collections

          Author and article information

          Chinese Journal of Natural Medicines
          20 May 2018
          : 16
          : 5
          : 339-346
          1Jiangsu Key Laboratory of Drug Screening and Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, China
          2First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China
          Author notes
          *Corresponding author: LIU Jun, Tel: +86-25-83271043; Fax: +86-25-83271043; E-mail: junliu@ 123456cpu.edu.cn ; SUN Hong-Bin, Tel: +86-25-83271043; Fax: +86-25-83271043, hbsun2000@ 123456yahoo.com

          ΔThese authors contributed equally to this work.

          These authors have no conflict of interest to declare.

          Copyright © 2018 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.
          Funded by: National Natural Science Foundation of China
          Award ID: 81673443
          Award ID: 81373303
          Award ID: 31501182
          Funded by: Fundamental Research Funds for the Central Universities
          Award ID: 26302017ZD05
          This work was supported by National Natural Science Foundation of China (Nos. 81673443, 81373303 and 31501182) and by the Fundamental Research Funds for the Central Universities (No. 26302017ZD05).


          Comment on this article